

CureGenetics secures \$17 M in Series A Financing

August 7, 2018 | News

The company intends to use the proceeds to further optimize its gene editing and delivery platform.



Cure Genetics Co., Ltd., a biotechnology company dedicated to the development of life-saving transformative medicines and molecular diagnostics using best-in-class gene editing technologies, announced the closing of \$17 million Series A financing, led by Qiming Venture Partners.

Additional investors included CTS Capital and Ascendin Investment. The company intends to use the proceeds to further optimize its gene editing and delivery platform, to sponsor IND application and clinical trials, and to develop its diverse pipelines.

"Being a unique player of this field, we have recruited top-tier scientists and business partners to develop and promote our proprietary technology platform," said Dr. Yuanyuan Xu, Co-founder and CEO of CureGenetics. "We are delighted by the votes of confidence from all the investors, and this financing puts us in strong position to accelerate the development of multiple pipelines, and to keep investing in these game-changing technologies."